A scientific team supported by the National Institutes of Health has created a tiny, bioengineered 3-D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal ...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional ...
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
DelveInsight’s, “Multifocal Motor Neuropathy Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Multifocal Motor Neuropathy pipeline landscape.
> Baxter International ($BAX) gained FDA approval to use its Gammagard Liquid 10% (immune globulin infusion) as a treatment for multifocal motor neuropathy, the first ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: Dianthus Therapeutics, ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback